Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type-b conjugate vaccine (GlaxoSmithKline)

N/A

Report date: 2023/04/21 13:49:46

Base Information

Drug NameDiphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type-b conjugate vaccine (GlaxoSmithKline)
Drug Alias NameDiphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type-b (Hib) conjugate vaccine (adsorbed)GSK2036874A (DTPw-HBV-IPV/Hib)Infanrix HeXaGSK-2036874AGSK-217744 +[6] 
ClassificationVaccines > Development/production technology > Conjugated vaccineVaccines > Application > Prophylactic vaccineVaccines > Biological material > Bacterial vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsRubellaMumpsMeasles +[13] 
Global Approved IndicationsHepatitis BPoliomyelitisTetanus +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2000/10/23
Country/TerritoryCzechiaSingaporeThailand +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Biologicals SA
Inactive CompaniesGlaxosmithkline PlcSanofi PasteurNovartis Vaccines +[4] 
Active IndicationsHepatitis BPoliomyelitisTetanus +[6] 
Inactive IndicationsRubellaMumpsMeasles +[7] 

Other Information

ATC CodeJ07CA09
Related LinksN/A